Filgotinib
Chemical compound / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Filgotinib?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Filgotinib, sold under the brand name Jyseleca, is a medication used for the treatment of rheumatoid arthritis (RA).[3] It was developed by the Belgian-Dutch biotech company Galapagos NV.[6]
Quick Facts Clinical data, Trade names ...
Clinical data | |
---|---|
Trade names | Jyseleca |
Other names | GLPG0634, GS-6034[1] |
License data | |
Routes of administration | By mouth |
Drug class | Janus kinase inhibitor |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Elimination half-life | 6 hours[5] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG | |
ChEMBL | |
PDB ligand | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C21H23N5O3S |
Molar mass | 425.51 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
Close
The most common side effects include nausea (feeling sick), upper respiratory tract infection (nose and throat infection), urinary tract infection and dizziness.[3]
Filgotinib was approved for medical use in both the European Union and Japan in September 2020.[3][6][7]